Impact of Signaling and Function of Individual Incretin Receptors on the Pharmacology of Incretin-Based Drugs
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pharmacology".
Deadline for manuscript submissions: 28 February 2027
Special Issue Editor
Interests: cardiovascular G protein-coupled receptors (GPCRs); heart failure; autonomic control of the circulation; adrenal physiology and pharmacology; adrenergic receptors; angiotensin receptors; signal transduction; gene therapy; aldosterone pharmacology; GPCR-Kinases; arrestins; G protein signaling
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Incretin receptors are critical G protein-coupled receptors (GPCRs) that regulate glucose homeostasis and metabolic function. Located primarily in pancreatic beta cells, the two (currently) most studied examples are the glucagon-like peptide-1 (GLP-1) receptor (GLP-1R) and the glucose-dependent insulinotropic polypeptide (GIP) receptor (GIPR). Since they mediate the actions of vastly popular weight loss medications, such as semaglutide and tirzepatide, interest in the physiology and pharmacology of these receptors has skyrocketed over the past few years. Relatively recent research in this area has made two important concepts abundantly clear: a) The involvement of incretin receptors in organ/tissue physiology and pathophysiology extends far beyond the pancreas, the brain, or the cardiovascular system, and b) incretin receptors share some biological/pharmacological properties (after all, they all belong to the same (B1) class of GPCRs), but they also appear to display several important differences in their signaling and functional properties in various tissues/organs. For example, signaling-wise, GIPR shows much stronger preference for b-arrestins than the GLP-1R does, or physiology-wise, GLP-1R suppresses, whereas GIPR stimulates glucagon secretion.
In this Special Issue, we are pleased to invite you to contribute articles focusing on exploring the various signaling and functional properties of individual incretin receptors, as they pertain to organ physiology, disease pathophysiology, or drug design and development. Studies elucidating pharmacological and physiological differences (but also similarities) among individual incretin receptors, and how they factor into incretin-based drug pharmacology, are particularly encouraged. Original investigations, review articles, and short communications are all welcome. Research areas may include (but are not limited to) the following:
- Signal transduction;
- Obesity/Adipose tissue (patho)physiology;
- Appetite regulation;
- Drug design and development;
- Autonomic signaling;
- Atherosclerosis;
- Cancer;
- Hypertension;
- Cognitive dysfunction/Neurodegeneration;
- Heart failure;
- Cardiac Arrhythmias;
- Metabolic Syndrome/Insulin resistance/Diabetes mellitus;
- Stem cell biology/physiology;
- Acute Coronary Syndrome;
- Inflammation;
- Autoimmune diseases;
- Cardiovascular endocrinology;
- End-organ damage;
- Respiratory diseases;
- Reproductive (patho)physiology;
- Bone remodeling;
- Muscle homeostasis/wasting;
- Strategies for preventing lean mass loss and weight regain.
We look forward to receiving your contributions.
Dr. Anastasios Lymperopoulos
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- drug development
- incretin
- signal transduction
- obesity
- metabolism
- G protein-coupled receptor
- receptor pharmacology
- translational medicine
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
